Skip to content
Clinical Trials – home

Pauls Stradins Clinical University Hospital

Verified siteinfo

Latvia Pilsonu Iela 13, 1002 Riga, Latvia

  • 39 trials recruiting
  • Colitis ulcerative · Crohn's disease · Pulmonary arterial hypertension
  • Adults and children

About Specializations

Pauls Stradins Clinical University Hospital in Riga, Latvia specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Pulmonary arterial hypertension, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology research, focusing on innovative therapies for conditions such as Crohn's Disease and Ulcerative Colitis. The center's work in this field aims to improve patient outcomes through targeted therapies and long-term safety evaluations.

  • Moderate to Severe Crohn's Disease
  • Ulcerative Colitis

By exploring novel treatment regimens, the center contributes significantly to the understanding and management of inflammatory bowel diseases.

Cardiology

Specializing in cardiology, the center conducts pivotal studies on conditions like Atrial Fibrillation and Chronic Heart Failure. These studies aim to enhance therapeutic strategies and improve the quality of life for patients with cardiovascular diseases.

  • Atrial Fibrillation
  • Chronic Heart Failure with Preserved Ejection Fraction

The center's research efforts are instrumental in developing safer and more effective cardiovascular treatments.

Neurology

In the field of neurology, the center is renowned for its research on Multiple Sclerosis and related disorders. The focus is on evaluating the efficacy of new treatments and understanding disease mechanisms to offer better therapeutic options.

  • Relapsing Multiple Sclerosis

Through its cutting-edge research, the center is paving the way for advancements in neurological care and treatment.

Endocrinology

The center's endocrinology research is dedicated to improving the management of Type 2 Diabetes and its complications. By investigating new drug combinations and their effects on diabetic conditions, the center aims to enhance patient care and treatment outcomes.

  • Type 2 Diabetes

These studies are crucial in developing comprehensive treatment plans for diabetes management.

Ophthalmology

In ophthalmology, the center is advancing research on Age-related Macular Degeneration and Diabetic Retinopathy. The focus is on evaluating the efficacy of novel treatments to prevent vision loss and improve eye health.

  • Geographic Atrophy Secondary to AMD
  • Diabetic Retinopathy

The center's work is vital in developing new therapies that address the underlying causes of these eye conditions.

Rheumatology

Focusing on rheumatology, the center conducts research on Psoriatic Arthritis and Chronic Urticaria. These studies aim to improve treatment efficacy and patient quality of life through innovative therapeutic approaches.

  • Psoriatic Arthritis
  • Chronic Urticaria

The center's research is instrumental in developing new treatment paradigms for these chronic conditions.

Oncology

The center's oncology research is focused on improving treatment strategies for Small Cell Lung Cancer and Bladder Cancer. By evaluating new drug combinations and their efficacy, the center aims to enhance cancer treatment outcomes.

  • Limited-Stage Small Cell Lung Cancer
  • Non-Muscle Invasive Bladder Cancer

These studies are crucial in advancing cancer care and providing new hope for patients.

Infectious Diseases

In the realm of infectious diseases, the center is pioneering research on Complicated Urinary Tract Infections and Bacterial Pneumonia. The focus is on assessing the efficacy and safety of novel antibiotic regimens to combat resistant infections.

  • Complicated Urinary Tract Infections
  • Hospital-Acquired Bacterial Pneumonia

The center's research is vital in addressing the growing challenge of antibiotic resistance.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Pilsonu Iela 131002 RigaLatvia
Recruiting now
39 trials
Conditions studied
87
Partner status
Verified site

More sites in RigaLatvia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

145 clinical trials

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:LatviaLatvia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.